Dr Steve Welch Birmingham Heartlands Hospital

Slides:



Advertisements
Similar presentations
Antimicrobial Prescribing in the Management of COPD
Advertisements

Hepatitis B & Hepatitis C in HIV
Cough or Difficulty of Breathing. One of the most common infections among children May be pneumonia or a less serious respiratory infection Strep. pneumoniae.
Workshop 4: Il late-presenter Moderatori: G. Ippolito, M. Moroni Discussant: R. Iardino Quando cominciare: Impatto delle comorbidità A. Cingolani.
2 nd line and recent ARVs prices and access issues Carmen Pérez Casas Access Campaign MSF May 2006.
St Marys Hospital Ingrid V. Bassett, MD, MPH Massachusetts General Hospital Harvard Medical School May 25, 2010 Who Starts ART in Durban, South Africa?
TB & HIV Infection: Treatment
TB & HIV Infection: Treatment Your name Institution/organization Meeting Date International Standard 8, 13 TB & HIV Infection: Treatment Your name Institution/organization.
ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
TB and HIV Management Dr A.L. Pozniak Chelsea and Westminster Hospital London, UK.
1 TREATMENT AND PREVENTION SCALE-UP: THE SOUTH AFRICAN EXPERIENCE By Dr Moolman Team South Africa.
Management of ART in Albania : From the European Guidelines to the real practice. Arjan Harxhi MD, MSc, PhD University Hospital Center of Tirana Mother.
HIV Situation in India Dr Sunil Gaikwad.
EPIDIOMOLGY OF HIV IN NIGERIA by Dr Ibrahim M Kida.
The Impact of Drug Benefit Caps Geoffrey Joyce, PhD.
Managing patient infected with HIV in a Government health Clinic – Six years experience Dr. Norsiah Ali PMC MD(USM),MMed (UM) Family Medicine Specialist,
ART in HIV-Infected Patients with TB: Research Priorities Group II Facilitator: David Cohn Rapporteur: Soumya Swaminathan.
Tuberculosis and the Immune Reconstitution Inflammatory Syndrome (IRIS) Bob Colebunders.
Rational Drug Use Supported by USAID Prescribing, Dispensing, Counseling and Adherence in ART Programs.
Rational Drug Use Supported by USAID Prescribing, Dispensing, Counseling and Adherence in ART Programs.
Key1 World Bank Training Program on HIV/AIDS Drugs Training Module 3 Selection and Quantification based on the World Bank document Battling HIV/AIDS: A.
The Evolving Adult Immunization Platform
Drug treatment for chronic hepatitis B Implementing NICE guidance NICE technology appraisal guidance 96, 153, 154, 173 Updated 2009.
Miriam Lichtner Dipartimento di Malattie Infettive e Sanità Pubblica Sapienza Università di Roma Polo Pontino Componente dell Italian National Focal Point.

Phases of HIV/AIDS 1. Infection 2. Window period 3. Seroconversion 4. Asymptomatic period 5. HIV/AIDS - related illness 6. AIDS.
Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.
Hellen Muttai, MBChB, MPH Clinical Care Manager
Slide #1 Case Study Objectives: Darrel At the conclusion of this case study, learners will be better able to: Predict challenges to HIV care and treatment.
©2007 World Heart Federation … Updated October 2008 Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease.
Huiswerkoplossings.  1) As x = -1 dan is y = -2(-1) – 8 = 2 – 8 = -6 As x = -2 dan is y = -2(-2) – 8 = 4 – 8 = -4 As x = -3 dan is y = -2(-3) – 8 = 6.
 What is an eating disorder  What are the types of eating disorders  What are the treatment options  What is an RD’s role in eating disorders.
Treatment and Prevention of Opportunistic Infections: Options for the Caribbean Region Excerpted from presentation by Jonathan E. Kaplan, M.D.
 Prevents 14 million cases of disease in the US each year  Objectives reflect a mobile world society  People continue to contract diseases that are.
Treatment as Prevention (TasP)
Case year-old white UK male Living in non-urban Eastern England Married Grown-up children 1.
ARV overview and toxicity Dr Francois Venter Reproductive Health Research Unit University of the Witwatersrand.
HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.
International AIDS Society, Industry Liaison Forum, Montreal, 8 th February 2009 Paediatric HIV Research: Status, priorities and ethical considerations.
M ANAGING ARV REGIMEN FAILURE IN THE HIV INFECTED CHILD Dr L Keet Centre of Excellence HIV Directorate.
Review of HIV and Opportunistic Infections (OI) in Children
1 ARV therapy in children - Clinical & Pharmacological Effects: How much do we know and how much do we need to know? Mark Cotton KID-CRU, Tygerberg Children’s.
Children and resistance to HIV: CHIPS data Dr Katherine Boyd on behalf of Collaborative HIV Paediatric Study (CHIPS) and the UK HIV Drug Resistance Database.
ARV Nurse Training Programme Marcus McGilvray & Nicola Willis
HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.
Working with HIV CASE PRESENTATIONS: SARAH BARBER CNS HIV
Dr. Abdulkarim Alhethail
Chronic HIV Infection Clinical Manifestations Opportunistic Infections O.I. Prophylaxis.
Initial Evaluation of the HIV+ Patient Mitchell D. Feldman, MD Professor UCSF.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
BHIVA national clinical audit of ART Dr Margaret Johnson, Chair of BHIVA clinical audit committee Dr Gary Brook Vice-Chair of BHIVA clinical audit committee.
1 Starting ART in the Context of Opportunistic Infections HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Guidelines for the use of antiretroviral agents in HIV infections in Taiwan, revised in 2002 by Infectious Diseases Society of the ROC and Taiwan AIDS.
NURSETRI, Nursing role in HIV care : an overview Jane Bruton Clinical Research Nurse.
Streptococcus pyogenes Team Case Study 2. The Diagnosis Ben Fallerez is a 12 year old boy going to school in France. He complained of a sore throat. The.
1 Monitoring The Patient on ARV Treatment HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.
History of Opportunistic Complications: Should This Remain An Exclusionary Criterion? Kathleen E. Squires, M.D. Associate Professor of Medicine Keck School.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
1 HIV Clinical Staging HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Prophylaxis of Opportunistic Infections
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
A Call to Action Children – The missing face of AIDS.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Claire Gamble Friday 30th June 2017
Dr Immaculate Kariuki Consultant Paediatrician Nairobi, Kenya
When to START During an OI
Anthony D Harries Ministry of Health, Malawi
Presentation transcript:

Dr Steve Welch Birmingham Heartlands Hospital 3rd Annual Conference of the Children’s HIV Association ‘Young People and HIV: Back to the Future’ Dr Steve Welch Birmingham Heartlands Hospital Friday 15 May, The Bridgewater Hall, Manchester

Other opportunistic infections Steve Welch Heartlands Hospital, Birmingham 3rd Annual CHIVA Conference Manchester, 15th May 2009

Other opportunistic infections Cases When to start ART in OI? Effect of OI on HIV – CMV Areas not covered - guidance

Case 15 yo Recurrent pneumonia and then PcP Started kivexa, efavirenz Good VL, CD4 response VL undetectable for more than 1 year CD4 400

1st cxr 5/11/08

Why? Not adherent to medication? On wrong medication? Should still be on septrin? Has developed resistance to penicillin? Susceptible because of rheumatic fever? That’s what happens Blame National Express

Effect of HAART on bacterial infections in children with HIV

Effect of HAART on bacterial infections in children with HIV

Effect of HAART on bacterial infections in children with HIV

Prevention of bacterial disease HAART Antibiotic prophylaxis Immunisation Immunoglobulins

Why? Not adherent to medication? On wrong medication? Should still be on septrin? Has developed resistance to penicillin? Susceptible because of rheumatic fever? That’s what happens Blame National Express

15yr old Zimbabwean girl In UK 2005 Unusual rash 2yrs Further work up Nodular, pruritic Biopsy : nodular prurigo Hiv 1positive (mar 2006) Further work up Low CD4 4%(19) Lymphadenopathy Viral load : 276000c/ml

Drug Adherence issues Kivexa/efavirenz/septrin (April 2006) Kaletra /lamivudine/abacavir(Nov 2006) Lamivudine (dec 2006) Kaletra/Truvada (from January 2007) Adherence issues Poor drug compliance / DNA PEG inserted Oct 2007 Poor response to treatment/ viral resistance Counselling

Should she be on MAI prophylaxis?

MAI prophylaxis Evidence that it works: 90-95% reduction in incidence in adults by prophylaxis or HAART

MAI prophylaxis Recommended by US guidelines What are suitable agents? In what circumstances?

MAI prophylaxis What are suitable agents? Azithromycin Clarithromycin Rifabutin Rifampicin Clofazamine

MAI prophylaxis In what circumstances? CD4 < 50 At new diagnosis After starting treatment until immune reconstitution If not on treatment If not adherent to treatment

Case 13 yo from Zambia Weight loss, chronic cough Bronchiectasis Hi influenzae, pneumococcus VL 10 million CD4 2 (<1%) HLA B*5701 negative No significant resistance mutations Now has secondary fevers ALT 250

When should he start HAART? Now When fever abates and LFT’s back down When fever abates When LFT’s back down When completely stable Should have started before having RT and HLA result back

CROI 2008 Abstract142 Immediate vs Deferred ART in the Setting of Acute AIDS-related Opportunistic Infection: Final Results of a Randomized Strategy Trial, ACTG A5164 Andrew Zolopa*1, J Andersen2, L Komarow2, A Sanchez3, C Suckow4, I Sanne5, E Hogg6, W Powderly7, and ACTG A5164 Study Team 282 patients randomised to immediate (<14 days) or deferred (>4 weeks) ART PcP 63% Cryptococcal meningitis 13% Pneumonia 10% No progression and VL<50 48 v 45% BUT 14 v 24% progression to AIDS or death, faster time to undetectable VL and VD4 >50, >100

CROI 2009: 36cLB Early vs Delayed ART in the Treatment of Cryptococcal Meningitis in Africa Azure Makadzange*1,2, C Ndhlovu2, K Takarinda2, M Reid2, M Kurangwa2,Vhikwasha2, and J Hakim2 54 patients randomised to early (<72 hours) v late (10 weeks) ART in cryptococcal meningitis: Mortality 82% v 37%

Case 7 yo from Zimbabwe VL 2 million CD4 10 (1%) Presents with allergic reaction to septrin Ongoing fevers and symptoms

What is the likely diagnosis? Septrin allergy Bacterial infection Common respiratory virus TB Atypical Mycobacteria PcP Candida Cryptococcus Other

What are alternatives to septrin?

What are alternatives to septrin? Dapsone Atovaquone Pentamidine Fansidar (Pyrimethamine-sulfadoxine)

4-month old girl Birthweight 4.1 kg (75th centile) Now 5.2 kg (2nd centile) Respiratory distress, diagnosed PcP Good response to ART. CD4 2300 (35%) When can she stop septrin?

AIDS 2005

Stopping PcP prophylaxis Cd4>15%, 200 for 6 months Cd4> 15%, 500 below age 5 Not in first 12-18 months of life?

What not covered? Immunisation Guideline Other OIs - cryptosporidia Varicella